ALP-201-neo
Pre-clinical- Indications
- Solid tumors
Company intelligence / Profile preview
Alpioner Therapeutics
Grenoble, Auvergne Rhône Alpes, Francealpionertx.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Preclinical
01
Overview
The company has demonstrated positive efficacy/safety profile in vitro and in animal models for their vaccine candidate. They are consolidating the preclinical package and preparing for tech transfer/upscaling to get GMP batches. Clinical trials on humans are set to begin in 2025.
- Therapeutic areas
- PulmonologyOncologyInfectious Diseases
- Modalities
- VaccinesImmunotherapies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Alpioner Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpioner Therapeutics.